TITLE

Medical biochemistry

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS47
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Stability of maternal serum markers for Down syndrome during transportation,' by J. Masse et al.
ACCESSION #
9708236419

 

Related Articles

  • Current state of screening for Down's syndrome. Holding, Stephen // Annals of Clinical Biochemistry;Jan2002, Vol. 39 Issue 1, p1 

    Down's syndrome has an incidence of about 1·3 per 1000 births. Antenatal testing for this disorder on the basis of maternal age has been common practice (increasing age is associated with increasing risk of having an affected pregnancy). Since the late 1980s it has been possible to calculate...

  • Candidate epigenetic biomarkers for non-invasive prenatal diagnosis of Down syndrome. Old, Frobert W.; Crea, Francesco; Puszyk, William; Hultén, Anita // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Aug2007, Vol. 15 Issue 2, p227 

    This report describes the first identification and characterization of three chromosome-21-specific DNA sequences (and reference sequences from other chromosomes) that are differentially methylated between peripheral blood and placental tissue, with the aim of providing epigenetic biomarkers for...

  • Cost-effectiveness analysis for triple markers serum screening for Down's syndrome in Thai setting. Wiwanitkit, Viroj // Indian Journal of Human Genetics;Apr-Jun2014, Vol. 20 Issue 2, p153 

    BACKGROUND: Down's syndrome is an important congenital chromosomal disorder that can be seen around the world. The antenatal screening for this disorder is an important processing in present obstetrics. OBJECTIVE: Due to the concept of first do no harm, the use of noninvasive test is...

  • The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Rafii, Michael S.; Wishnek, Hannah; Brewer, James B.; Donohue, Michael C.; Ness, Seth; Mobley, William C.; Aisen, Paul S.; Rissman, Robert A. // Frontiers in Behavioral Neuroscience;Sep2015, Vol. 9, p1 

    To gain further knowledge on the preclinical phase of Alzheimer's disease (AD), we sought to characterize cognitive performance, neuroimaging and plasma-based AD biomarkers in a cohort of non-demented adults with down syndrome (DS). The goal of the down syndrome biomarker Initiative (DSBI) pilot...

  • Prenatal findings of patients diagnosed with Down syndrome: The value of ultrasound and biochemical screening. Özdemira, Halis; Kalaycı, Hakan; Uysal, Nihal Şahin; Parlakgümüş, Huriye Ayşe; Çok, Tayfun; Tarıma, Ebru; Yanık, Filiz Bilgin // Eastern Journal of Medicine;2015, Vol. 20 Issue 2, p76 

    The aim of this study was to determine the association among ultrasound findings, biochemical markers, and Down syndrome. A retrospective analysis was conducted of the files and electronic records of 70 Down syndrome patients who were diagnosed in the prenatal or postnatal periods between July...

  • Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimer's Disease. Gandy, Sam // New England Journal of Medicine;8/30/2012, Vol. 367 Issue 9, p864 

    The author comments on a study which explored imaging and biomarker assessments in presymptomatic autosomal dominant Alzheimer's disease. He questions the implication of the study's findings for patients with Down's syndrome. According to the author, amyloid-beta-lowering therapies in Down's...

  • Screening Downova syndromu v prvním, druhém nebo obou trimestrech? Belošovičová, Hana; Calda, Pavel // Actual Gynecology & Obstetrics / Aktuální Gynekologie a Porodn;2012, Vol. 4, p14 

    The aim of this article is to give an overview of current status of worldwide discussion of effectivness of Down's syndrome screeening programs. This article explaines structure of basic screening strategies and review of their published evidence. In this article screening tests of the first...

  • Medians for second-trimester maternal serum markers: geographical differences and variation caused by median multiples-of-median equations. Vranken, G.; Reynolds, I.; van Nueten, J. // Journal of Clinical Pathology;Jun2006, Vol. 59 Issue 6, p639 

    Objectives: To establish gestational age-specific mid-trimester normal medians for the prenatal serum markers α fetoprotein (AFP), human chorionic gonadotropin (HCG) and unconjugated oestriol (uE3) for a Belgian population by using the Beckman Coulter Access chemiluminiscent immunoassays; to...

  • Weight correction of MoM values: which method? Reynolds, T. M.; Vranken, G.; Van Nueten, J. // Journal of Clinical Pathology;Jul2006, Vol. 59 Issue 7, p16 

    Background: Adjusting maternal serum markers for maternal weight is considered to be a standard practice when screening for pregnancies associated with Down's syndrome. The choice of model for taking maternal weight into account is, however, rarely explicitly evaluated. Method: The relationship...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics